<DOC>
	<DOCNO>NCT01372228</DOCNO>
	<brief_summary>The goal research study establish chimerism avoid graft-versus-host-disease ( GVHD ) patient inherit metabolic disorder .</brief_summary>
	<brief_title>Phase I/II Pilot Study Mixed Chimerism Treat Inherited Metabolic Disorders</brief_title>
	<detailed_description>The objective study establish chimerism follow reduce intensity condition grade III/IV GVHD . The primary endpoint follow production miss enzyme ≥ 10 % normal level day 180 post-transplant &gt; 90 % patient .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Mucopolysaccharidosis II</mesh_term>
	<mesh_term>Adrenoleukodystrophy</mesh_term>
	<mesh_term>Pick Disease Brain</mesh_term>
	<mesh_term>Aphasia , Primary Progressive</mesh_term>
	<mesh_term>Frontotemporal Dementia</mesh_term>
	<mesh_term>Mucopolysaccharidosis I</mesh_term>
	<mesh_term>Mannosidase Deficiency Diseases</mesh_term>
	<mesh_term>alpha-Mannosidosis</mesh_term>
	<mesh_term>Mucopolysaccharidosis III</mesh_term>
	<mesh_term>Tay-Sachs Disease</mesh_term>
	<mesh_term>Leukodystrophy , Metachromatic</mesh_term>
	<mesh_term>Niemann-Pick Diseases</mesh_term>
	<mesh_term>Niemann-Pick Disease , Type A</mesh_term>
	<mesh_term>Niemann-Pick Disease , Type C</mesh_term>
	<mesh_term>Leukodystrophy , Globoid Cell</mesh_term>
	<mesh_term>Sandhoff Disease</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients must confirm diagnosis inherit metabolic disorder / inborn error metabolism . Diagnosis confirm appropriate test ( ) ( enzyme and/or mutation analysis ) study entry . Patients must eligible myeloablative chemotherapy preparative regimen transplant due age , comorbidities organ dysfunction . Inborn error metabolism / Inherited Metabolic Disorders ( IMD ) eligible study include follow : Hurler Syndrome ( MPS I ) HurlerScheie Syndrome early neurologic involvement and/or sensitization ERT Hunter Syndrome ( MPS II ) Sanfilippo Syndrome ( MPS III ) Krabbe Disease ( Globoid Leukodystrophy ) Metachromatic Leukodystrophy ( MLD ) Adrenoleukodystrophy ( ALD AMN ) Sandhoff Disease Tay Sachs Disease Pelizaeus Merzbacher ( PMD ) NiemannPick Disease Alphamannosidosis 2 . Patients must adequate function organ system measure : Creatinine le equal 2.0 mg/dl creatinine clearance ≥60 cc/min/1.73m2 . Newborns must creatinine clearance ≥ 25 cc/min . For baby less equal 3 month age , raw value glomerular filtration rate ( GFR ) must ≥ 1 cc/kg/min . Hepatic transaminase ( ALT/AST ) 2.5 x normal , bilirubin &lt; 2.0mg/dl Normal cardiac function echocardiogram radionuclide scan ( ejection fraction shorten fraction &gt; 80 % normal value age ) Pulmonary function test ( PFTs ) demonstrate force expiratory volume one second ( FEV1 ) ≥50 % predicted age . If child young unable perform PFTs , cry vital capacity result &gt; 50 % normal value age rest pulse oximeter &gt; 92 % room air clearance pulmonologist require . 3 . Patient must relate donor ( identical mismatch 1 , 2 3 Human Leukocyte Antigen ( HLA ) A , B DR locus ) . 4 . Patient , parent , legal guardian must give write informed consent accord FDA guideline . 5 . Patients must minimum life expectancy least 6 month . 6 . Female patient childbearing potential pregnant lactating/breastfeeding must either surgically sterile , postmenopausal ( menses previous 12 month ) , must practice effective method birth control determine investigator ( e.g. , oral contraceptive , double barrier method , hormonal injectable implanted contraceptive , tubal ligation , partner vasectomy ) . 7 . There upper low age limit study . Exclusion Criteria 1 . Patients uncontrolled seizure , apnea , evidence recurrent uncontrolled aspiration , need chronic mechanical ventilation . 2 . Patients allogeneic stem cell transplant cytoreductive therapy past 6 month . 3 . Subjects must previous radiation therapy would preclude total body irradiation ( TBI ) ( determine radiation therapist ) 4 . Uncontrolled infection severe concomitant disease , judgment Principal Investigator , could tolerate reduce intensity transplantation . 5 . Subjects positive human immunodeficiency virus ( HIV ) antibody test result 6 . Subjects pregnant , indicate positive serum human chorionic gonadotropin ( HCG ) test 7 . Subjects whose donor pregnant time intend transplant 8 . Subjects childbearing potential practicing adequate contraception define investigator site 9 . Jehovah 's witness unwilling transfuse 10 . Patients comorbid condition , view Principal Investigators , render patient high risk treatment complication regimen related morbidity/mortality . 11 . Lack related donor</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>hematopoietic stem cell transplant , chimerism , leukodystrophy</keyword>
</DOC>